DE602004024539D1 - Verfahren und systeme zur diagnose von nicht das zentrale nervensystem (zns) betreffenden krankheiten in zns-proben - Google Patents

Verfahren und systeme zur diagnose von nicht das zentrale nervensystem (zns) betreffenden krankheiten in zns-proben

Info

Publication number
DE602004024539D1
DE602004024539D1 DE602004024539T DE602004024539T DE602004024539D1 DE 602004024539 D1 DE602004024539 D1 DE 602004024539D1 DE 602004024539 T DE602004024539 T DE 602004024539T DE 602004024539 T DE602004024539 T DE 602004024539T DE 602004024539 D1 DE602004024539 D1 DE 602004024539D1
Authority
DE
Germany
Prior art keywords
cns
systems
samples
distractive
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004024539T
Other languages
English (en)
Inventor
Osvaldo L Podhajcer
Fernando Juan Pitossi
Marcelo Rubinstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GENTRON LLC
Original Assignee
GENTRON LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GENTRON LLC filed Critical GENTRON LLC
Publication of DE602004024539D1 publication Critical patent/DE602004024539D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
DE602004024539T 2003-07-03 2004-07-02 Verfahren und systeme zur diagnose von nicht das zentrale nervensystem (zns) betreffenden krankheiten in zns-proben Active DE602004024539D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48472603P 2003-07-03 2003-07-03
US48468303P 2003-07-03 2003-07-03
PCT/US2004/021543 WO2005007892A1 (en) 2003-07-03 2004-07-02 Methods and systems for diagnosis of non-cenral nervous system (cns) diseases in cns samples

Publications (1)

Publication Number Publication Date
DE602004024539D1 true DE602004024539D1 (de) 2010-01-21

Family

ID=34083317

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004024539T Active DE602004024539D1 (de) 2003-07-03 2004-07-02 Verfahren und systeme zur diagnose von nicht das zentrale nervensystem (zns) betreffenden krankheiten in zns-proben

Country Status (8)

Country Link
US (2) US20060263783A1 (de)
EP (1) EP1649062B1 (de)
JP (1) JP2007531494A (de)
AT (1) ATE451475T1 (de)
AU (1) AU2004258101B2 (de)
CA (1) CA2531281A1 (de)
DE (1) DE602004024539D1 (de)
WO (1) WO2005007892A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010509909A (ja) * 2006-11-16 2010-04-02 ジェントロン リミテッド ライアビリティー カンパニー 癌診断のための方法、システム、および組成物
EP2167634A4 (de) * 2007-07-16 2013-11-06 California Inst Of Techn Arrays, substrate, vorrichtungen, verfahren und systeme zur erkennung von zielmolekülen
WO2009020058A1 (ja) * 2007-08-03 2009-02-12 Keio University 脱髄病変へのドラッグデリバリーシステム及び脱髄病変の生化学的マーカー
US9125384B2 (en) 2007-10-18 2015-09-08 Riken Mouse having human leukemic stem cell and leukemic non-stem cell amplified therein, and method for production thereof
WO2010030293A1 (en) * 2008-09-15 2010-03-18 Gentron, Inc. Methods, systems, and compositions for cancer diagnosis
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
JP2011149859A (ja) * 2010-01-22 2011-08-04 Igaku Seibutsugaku Kenkyusho:Kk 食道癌マーカー
US20130151197A1 (en) * 2011-11-23 2013-06-13 General Electric Company Automated performance measurement processes and systems
US8912159B2 (en) * 2012-02-24 2014-12-16 National Institutes Of Health (Nih) Analyzing semaphorin7a (Sema7A) levels for assessing cancer metastatic potential and methods of treatment
EP4148118A1 (de) 2012-08-24 2023-03-15 Yale University System, vorrichtung und verfahren für multiplex-erkennung mit hohem durchsatz
EP3227684B1 (de) 2014-12-03 2019-10-02 Isoplexis Corporation Analyse und screening für die sekretionprofile von zellen
US11353448B2 (en) 2015-02-13 2022-06-07 California Institute Of Technology Methods and compositions for quantifying metabolites and proteins from single cells
EP3262190B1 (de) * 2015-02-24 2021-09-01 Ruprecht-Karls-Universität Heidelberg Biomarkeranordnung für den nachweis von krebs
EP4036578A1 (de) 2016-11-11 2022-08-03 Isoplexis Corporation Zusammensetzungen und verfahren zur gleichzeitigen genomischen, transkriptomischen und proteomischen analyse von einzelzellen
EP3545284A4 (de) 2016-11-22 2020-07-01 Isoplexis Corporation Systeme, vorrichtungen und verfahren für die zellerfassung und verfahren zur herstellung davon
KR102207699B1 (ko) * 2019-06-24 2021-01-26 재단법인 대구경북첨단의료산업진흥재단 뇌미세혈관 손상 뇌질환 진단용 바이오 마커 조성물
KR20210000253A (ko) * 2019-12-16 2021-01-04 재단법인 대구경북첨단의료산업진흥재단 뇌미세혈관 손상 뇌질환 진단용 바이오 마커 조성물
KR102207697B1 (ko) * 2019-06-24 2021-01-26 재단법인 대구경북첨단의료산업진흥재단 뇌미세혈관 손상 뇌질환 진단용 바이오 마커 조성물
KR102100588B1 (ko) * 2019-06-24 2020-04-13 재단법인 대구경북첨단의료산업진흥재단 뇌미세혈관 손상 뇌질환 진단용 바이오 마커 조성물
KR102207698B1 (ko) * 2019-06-24 2021-01-26 재단법인 대구경북첨단의료산업진흥재단 뇌미세혈관 손상 뇌질환 진단용 바이오 마커 조성물
KR102207696B1 (ko) * 2019-06-24 2021-01-26 재단법인 대구경북첨단의료산업진흥재단 뇌미세혈관 손상 뇌질환 진단용 바이오 마커 조성물
KR20210000255A (ko) * 2019-12-16 2021-01-04 재단법인 대구경북첨단의료산업진흥재단 뇌미세혈관 손상 뇌질환 진단용 바이오 마커 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7676894A (en) * 1993-08-27 1995-03-21 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Convection-enhanced drug delivery
EP1132473A4 (de) * 1998-11-20 2002-06-12 Fuso Pharmaceutical Ind Serinprotease bssp6
JP2003505749A (ja) * 1999-02-23 2003-02-12 ワーナー−ランバート カンパニー 遺伝子発現プロファイリングに由来する情報の管理と提示のためのシステムと方法
WO2000070340A2 (en) * 1999-05-14 2000-11-23 Karolinska Innovations Ab Materials and methods relating to disease diagnosis
EP1268854A4 (de) * 2000-03-27 2003-05-02 Univ Jefferson Markerdetektion mit hoher spezifität
US6372250B1 (en) * 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
EP1339872A2 (de) * 2000-09-19 2003-09-03 Whitehead Institute For Biomedical Research Genetische marker für tumore
CN1526025A (zh) * 2001-05-16 2004-09-01 ��˹��ŵ�� 作为预后和治疗靶标的乳腺癌中表达的基因
KR20040064275A (ko) * 2001-11-09 2004-07-16 소스 프리시전 메디슨, 인코포레이티드 유전자 발현 프로파일을 이용한 질병의 동정, 모니터링,치료 및 생물학적 상태의 확인

Also Published As

Publication number Publication date
US20110251077A1 (en) 2011-10-13
AU2004258101B2 (en) 2010-12-23
JP2007531494A (ja) 2007-11-08
EP1649062A1 (de) 2006-04-26
WO2005007892A1 (en) 2005-01-27
AU2004258101A1 (en) 2005-01-27
ATE451475T1 (de) 2009-12-15
EP1649062B1 (de) 2009-12-09
US20060263783A1 (en) 2006-11-23
CA2531281A1 (en) 2005-01-27

Similar Documents

Publication Publication Date Title
DE602004024539D1 (de) Verfahren und systeme zur diagnose von nicht das zentrale nervensystem (zns) betreffenden krankheiten in zns-proben
DE60233485D1 (de) Verfahren zur diagnose, behandlung und prävention von knochenverlust
DE60239470D1 (de) Verfahren zur bewertung pathologischer krankheitszustände unter verwendung extrazellulärer rna
ATE493649T1 (de) Verfahren zur diagnose von polyzystischer nierenkrankheit
GB0514435D0 (en) Diagnostic method for brain damage-related disorders
WO2004022580A3 (en) Bh3 peptides and method of use thereof
MX2009007368A (es) Deteccion, tratamiento y monitoreo de la inflamacion, por medio del receptor de disparo expresado en la celula 1 mieloide (trem-1).
DE602006015966D1 (de) Verfahren zur vorhersage und überwachung einer unmittelbaren reaktion auf eine krebstherapie
WO2007140958A3 (en) Method for identifying whether a patient will be responder or not to immunotherapy
EA200600920A1 (ru) Иммуносорбентные исследования крови для оценки пароксизмальных церебральных разрядов
WO2007032876A3 (en) Biomarkers associated with age-related macular degeneration
WO2007080597A3 (en) Polynucleotide and polypeptide sequences and methods for diagnosis
WO2006121912A3 (en) Diagnostic methods for the detection of risk of neurodevelopmental disorders
ATE483982T1 (de) Liquordiagnostisches in vitro verfahren zur diagnose von demenz-erkrankungen und neuroinflammatorischen erkrankungen
ATE467834T1 (de) Oligosaccharid-biomarker für mucopolysaccharidosen und andere verwandte störungen
WO2010084327A3 (en) Methods
WO2006002240A8 (en) Computer systems and methods for constructing biological classifiers and uses thereof
WO2007050588A3 (en) Systems and methods for characterizing conditions of organs for transplantation
WO2020077341A8 (en) Methods and compositions for identifying and treating subjects at risk for poor car t cell therapy response
DE60122673D1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
ATE487947T1 (de) Verfahren zur diagnose und behandlung auf nr2- peptiden beruhender zerebrovaskulärer ereignisse
WO2004045376A3 (en) Screening methods to identify treatments for autoimmune disease
WO2010033951A3 (en) Methods for identification and prediction of multiple sclerosis disease and therapy response
DE602005023329D1 (de) VERFAHREN ZUR DIAGNOSE NICHT-KLEINZELLIGER LUNGENKARZINOME ÜBER DIE tRNA-DIHYDROURIDIN-SYNTHASEAKTIVITÄT VON URLC8
ATE472611T1 (de) Verfahren zur diagnose von sepsis durch analyse von cytokine mrna expression

Legal Events

Date Code Title Description
8364 No opposition during term of opposition